Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least 12 years of age~* Diagnosis of asthma~* Baseline lung function test results as determined by protocol and required and received treatment with inhaled corticosteroids and/or lung treatments specified in protocol within the timeframe and doses specified in the protocol~Exclusion Criteria:~* Has required treatment with non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers~* Had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): budesonide
- 3 (Type: ACTIVE_COMPARATOR): formoterol

Based on this trial design, predict the completion outcome and termination type (if applicable).